Last update May 31, 2022

Octreotide Acetate

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

It is an octapeptide analogue of somatostatin with similar properties but a longer duration of action. It is used in the treatment of neuroendocrine tumors, acromegaly, after pancreatic surgery, and in bleeding from esophageal varices and diarrhea associated with HIV. Subcutaneous or intravenous administration.

It is excreted in breast milk (colostrum) in small amounts and no problems were seen in an infant whose mother was treated with octreotide during pregnancy. (Maffei 2010)

No problems were seen in two infants whose mothers were treated with somatostatin analogues or octreotide during pregnancy and 12 and 4 months of lactation, respectively (Babinska 2021, Colao 1997). Another infant was breastfed (duration unknown) by a mother on Octreotide 20 mg daily with no problems reported. (Assal 2016)

It is used in neonates and young infants. (Costa 2018)

See below the information of this related product:

  • Somatostatin (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)


We do not have alternatives for Octreotide Acetate since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Octreotide Acetate in other languages or writings:


Octreotide Acetate belongs to this group or family:


Main tradenames from several countries containing Octreotide Acetate in its composition:


Variable Value Unit
Oral Bioavail. 33 %
Molecular weight 1.019 daltons
Protein Binding 40 - 65 %
VD 0.2 - 0.4 l/Kg
pKa 11.4 -
Tmax sc: 0.5 ; oral 1.7 - hours
0.2 - 2.7 hours
Theoretical Dose 0.0007 mg/Kg/d
Relative Dose 1.7 - 3.5 %


  1. Babinska A, Olszewska H, Sworczak K. Safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating. Neuro Endocrinol Lett. 2021 Nov 30;42(7):433-437. Abstract Full text (link to original source) Full text (in our servers)
  2. Costa KM, Saxena AK. Surgical chylothorax in neonates: management and outcomes. World J Pediatr. 2018 Apr;14(2):110-115. Abstract
  3. Assal A, Malcolm J, Lochnan H, Keely E. Preconception counselling for women with acromegaly: More questions than answers. Obstet Med. 2016 Mar;9(1):9-14. Abstract Full text (link to original source)
  4. Maffei P, Tamagno G, Nardelli GB, Videau C, Menegazzo C, Milan G, Calcagno A, Martini C, Vettor R, Epelbaum J, Sicolo N. Effects of octreotide exposure during pregnancy in acromegaly. Clin Endocrinol (Oxf). 2010 May;72(5):668-77. Abstract
  5. Hamdan MA, Gaeta ML. Octreotide and low-fat breast milk in postoperative chylothorax. Ann Thorac Surg. 2004 Abstract Full text (link to original source) Full text (in our servers)
  6. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab. 1997 Sep;82(9):2777-81. No abstract available. Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM